These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 14722443)

  • 1. Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).
    Eshleman SH; Guay LA; Mwatha A; Brown ER; Cunningham SP; Musoke P; Mmiro F; Jackson JB
    J Acquir Immune Defic Syndr; 2004 Feb; 35(2):126-30. PubMed ID: 14722443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8 weeks after single-dose nvp prophylaxis: HIVNET 012.
    Eshleman SH; Guay LA; Mwatha A; Cunningham SP; Brown ER; Musoke P; Mmiro F; Jackson JB
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):595-9. PubMed ID: 15242535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic linkage of nevirapine resistance mutations in HIV type 1 seven days after single-dose nevirapine.
    Jones D; Parkin N; Hudelson SE; Guay LA; Musoke P; Mmiro F; Jackson JB; Eshleman SH
    AIDS Res Hum Retroviruses; 2005 Apr; 21(4):319-24. PubMed ID: 15943576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.
    Eshleman SH; Guay LA; Wang J; Mwatha A; Brown ER; Musoke P; Mmiro F; Jackson JB
    J Acquir Immune Defic Syndr; 2005 Sep; 40(1):24-9. PubMed ID: 16123677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).
    Eshleman SH; Mracna M; Guay LA; Deseyve M; Cunningham S; Mirochnick M; Musoke P; Fleming T; Glenn Fowler M; Mofenson LM; Mmiro F; Jackson JB
    AIDS; 2001 Oct; 15(15):1951-7. PubMed ID: 11600822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.
    Eshleman SH; Hoover DR; Chen S; Hudelson SE; Guay LA; Mwatha A; Fiscus SA; Mmiro F; Musoke P; Jackson JB; Kumwenda N; Taha T
    J Infect Dis; 2005 Jul; 192(1):30-6. PubMed ID: 15942891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.
    Flys T; Nissley DV; Claassen CW; Jones D; Shi C; Guay LA; Musoke P; Mmiro F; Strathern JN; Jackson JB; Eshleman JR; Eshleman SH
    J Infect Dis; 2005 Jul; 192(1):24-9. PubMed ID: 15942890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.
    Flys TS; Chen S; Jones DC; Hoover DR; Church JD; Fiscus SA; Mwatha A; Guay LA; Mmiro F; Musoke P; Kumwenda N; Taha TE; Jackson JB; Eshleman SH
    J Acquir Immune Defic Syndr; 2006 Aug; 42(5):610-3. PubMed ID: 16773030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nevirapine resistance after single dose prophylaxis.
    Eshleman SH; Jackson JB
    AIDS Rev; 2002; 4(2):59-63. PubMed ID: 12152519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    Hudelson SE; McConnell MS; Bagenda D; Piwowar-Manning E; Parsons TL; Nolan ML; Bakaki PM; Thigpen MC; Mubiru M; Fowler MG; Eshleman SH
    AIDS; 2010 Feb; 24(4):557-61. PubMed ID: 20057308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV type 1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug-naive African women with subtypes A, C, and D.
    Church JD; Hudelson SE; Guay LA; Chen S; Hoover DR; Parkin N; Fiscus SA; Mmiro F; Musoke P; Kumwenda N; Jackson JB; Taha TE; Eshleman SH
    AIDS Res Hum Retroviruses; 2007 Jun; 23(6):764-8. PubMed ID: 17604538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of nevirapine (NVP) resistance mutations and HIV type 1 subtype in women from Abidjan (Côte d'Ivoire) after NVP single-dose prophylaxis of HIV type 1 mother-to-child transmission.
    Toni TD; Masquelier B; Lazaro E; Dore-Mbami M; Ba-Gomis FO; Téa-Diop Y; Kouakou K; Diby J; Sia E; Soppi S; Essien S; Schrive MH; Pinson P; Chenal H; Fleury HJ
    AIDS Res Hum Retroviruses; 2005 Dec; 21(12):1031-4. PubMed ID: 16379606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral resistance patterns and HIV-1 subtype in mother-infant pairs after the administration of combination short-course zidovudine plus single-dose nevirapine for the prevention of mother-to-child transmission of HIV.
    Chalermchockcharoenkit A; Culnane M; Chotpitayasunondh T; Vanprapa N; Leelawiwat W; Mock PA; Asavapiriyanont S; Teeraratkul A; McConnell MS; McNicholl JM; Tappero JW
    Clin Infect Dis; 2009 Jul; 49(2):299-305. PubMed ID: 19522656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).
    Eshleman SH; Becker-Pergola G; Deseyve M; Guay LA; Mracna M; Fleming T; Cunningham S; Musoke P; Mmiro F; Jackson JB
    J Infect Dis; 2001 Oct; 184(7):914-7. PubMed ID: 11509999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.
    Jackson JB; Becker-Pergola G; Guay LA; Musoke P; Mracna M; Fowler MG; Mofenson LM; Mirochnick M; Mmiro F; Eshleman SH
    AIDS; 2000 Jul; 14(11):F111-5. PubMed ID: 10983633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Applied Biosystems ViroSeq HIV-1 Genotyping System for sequence-based analysis of non-subtype B human immunodeficiency virus type 1 from Uganda.
    Mracna M; Becker-Pergola G; Dileanis J; Guay LA; Cunningham S; Jackson JB; Eshleman SH
    J Clin Microbiol; 2001 Dec; 39(12):4323-7. PubMed ID: 11724839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.
    Moorthy A; Gupta A; Bhosale R; Tripathy S; Sastry J; Kulkarni S; Thakar M; Bharadwaj R; Kagal A; Bhore AV; Patil S; Kulkarni V; Venkataramani V; Balasubramaniam U; Suryavanshi N; Ziemniak C; Gupte N; Bollinger R; Persaud D
    PLoS One; 2009; 4(1):e4096. PubMed ID: 19119321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Volmink J; Siegfried NL; van der Merwe L; Brocklehurst P
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003510. PubMed ID: 17253490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda.
    Troyer RM; Lalonde MS; Fraundorf E; Demers KR; Kyeyune F; Mugyenyi P; Syed A; Whalen CC; Bajunirwe F; Arts EJ
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):235-50. PubMed ID: 18284323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.